DOTmed January 17, 2025
Johnson & Johnson has acquired Intra-Cellular Therapies, a New Jersey-based biopharmaceutical company focused on treatments for central nervous system disorders, in a deal valued at $14.6 billion.
J&J will purchase all outstanding shares of Intra-Cellular Therapies at $132 per share in cash, a move that strengthens its neuroscience portfolio and signals its focus on mental health and neurodegenerative conditions.
Through the acquisition, J&J gains CAPLYTA (lumateperone), an FDA approved oral therapy for schizophrenia and bipolar I and II depression, both as monotherapy and adjunctive treatment. CAPLYTA is also under review by the FDA for use as an adjunctive treatment for major depressive disorder (MDD), with the potential to address one of the most common and debilitating mental health conditions.
“Building...
Today's Sponsors
Today's Sponsor